Nature-published mouse data showed the hybrid drug cut food intake, drove greater weight loss and improved blood-glucose control versus a GLP-1/GIP co-agonist, with some results stronger than a GLP-1-only drug.
The molecule uses GLP-1/GIP signaling as a cellular gateway, carrying lanifibranor into receptor-expressing cells and then activating five targets—GLP-1R, GIPR and three PPAR pathways.
That targeted delivery is meant to boost metabolic effects while limiting systemic exposure; researchers said gastrointestinal side effects were similar to existing incretin drugs, with no signs of fluid retention or anemia in tested measures.
The preclinical study also hinted at heart and liver benefits, but the team said human results remain uncertain because GIP receptors work differently in mice and people.
Helmholtz Munich researchers said the next step is to optimize the approach for humans and secure industry backing to move the therapy toward clinical trials.
This 'Trojan horse' drug conquered obesity in mice. Can it overcome the critical human trial hurdles that stopped previous breakthroughs?
With key trial data for lanifibranor due soon, is this new 'Trojan horse' its ultimate successor or a direct competitor?
Quintuple Agonist "Trojan Horse" Drug Shows Unprecedented Obesity Reduction in Mice: Next-Gen Therapy from Helmholtz Munich
Overview
A major breakthrough in obesity treatment has been achieved by Prof. Timo D. Müller's team at Helmholtz Munich, who introduced a novel 'quintuple agonist' drug. This innovative hybrid compound is designed to target five different metabolic pathways at once, offering a more comprehensive approach to weight management. In preclinical mouse studies, the drug showed promising results, appearing more effective than current GLP-1-based therapies. By aiming to surpass existing treatments, this new drug could mark a significant step forward in obesity care, though further research is needed to confirm its benefits in humans.